Solid Biosciences Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2014-01-01
- Employees
- 101
- Market Cap
- $353.1M
- Website
- http://www.solidbio.com
Clinical Trials
4
Active:2
Completed:1
Trial Phases
1 Phases
Phase 1:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 1
3 (100.0%)A Study of SGT-003 Gene Therapy in Duchenne Muscular Dystrophy (INSPIRE DUCHENNE)
Phase 1
Recruiting
- Conditions
- Duchenne Muscular Dystrophy
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2025-08-24
- Lead Sponsor
- Solid Biosciences Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT06138639
- Locations
- 🇬🇧
Great Ormond Street Hospital, London, United Kingdom
🇺🇸Arkansas Children's Hospital, Little Rock, Arkansas, United States
🇺🇸University of California, Los Angeles Medical Center, Los Angeles, California, United States
Evaluation of Home Based Assessments on Participants With DMD
Completed
- Conditions
- Duchenne Muscular Dystrophy
- First Posted Date
- 2022-12-20
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- Solid Biosciences Inc.
- Target Recruit Count
- 17
- Registration Number
- NCT05657938
- Locations
- 🇺🇸
Solid Biosciences, Charlestown, Massachusetts, United States
Microdystrophin Gene Transfer Study in Adolescents and Children With DMD
Phase 1
Active, not recruiting
- Conditions
- Duchenne Muscular Dystrophy
- First Posted Date
- 2017-12-11
- Last Posted Date
- 2025-08-03
- Lead Sponsor
- Solid Biosciences Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT03368742
- Locations
- 🇺🇸
David Geffen School of Medicine at UCLA, Los Angeles, California, United States
🇺🇸University of Florida, Gainesville, Florida, United States
News
No news found